Modulating the Tumor Microenvironment in Metastatic Osteosarcoma: Palladia/Losartan/Ladarixin Combination Therapy

condition(s)

osteosarcoma

eligibility information

Enrollment Deadline

Enrollment ends July 7, 2022

contact information